BACKGROUND: In renal cell carcinoma (RCC), glycosphingolipids monosialosyl globopentaosylceramide (MSGb5) and GalNAc disialosyl lactotetraosylceramide (GaINAcDSLc4) were shown to be predictors of metastasis. Here we extended the research using a larger cohort of patients with a longer follow-up period, and reevaluate their relationship to malignant potential, metastasis and prognosis in patients with RCC. PATIENTS AND METHODS: MSGb5 and GalNAcDSLc4 were examined in 114 primary RCCs by immunohistochemical method on cryostat sections. RESULTS: GalNAcDSLc4 was detected in 13.2% of RCCs and was associated with a significantly higher incidence of metastasis at the time of primary visit (60.0% vs. 31.3%, p=0.0419) as well as de novo metastasis during followup (33.3% vs. 14.7%), and a shorter survival (p=0.0399). MSGb5 was detected in 51.8% of tumors and was not related to clinocopathological characteristics or survival. CONCLUSION: RCC patients with tumors positive for GalNAcDSLc4 are at higher risk of metastasis at the time of diagnosis and during follow-up.
BACKGROUND: In renal cell carcinoma (RCC), glycosphingolipidsmonosialosyl globopentaosylceramide (MSGb5) and GalNAc disialosyl lactotetraosylceramide (GaINAcDSLc4) were shown to be predictors of metastasis. Here we extended the research using a larger cohort of patients with a longer follow-up period, and reevaluate their relationship to malignant potential, metastasis and prognosis in patients with RCC. PATIENTS AND METHODS: MSGb5 and GalNAcDSLc4 were examined in 114 primary RCCs by immunohistochemical method on cryostat sections. RESULTS:GalNAcDSLc4 was detected in 13.2% of RCCs and was associated with a significantly higher incidence of metastasis at the time of primary visit (60.0% vs. 31.3%, p=0.0419) as well as de novo metastasis during followup (33.3% vs. 14.7%), and a shorter survival (p=0.0399). MSGb5 was detected in 51.8% of tumors and was not related to clinocopathological characteristics or survival. CONCLUSION:RCCpatients with tumors positive for GalNAcDSLc4 are at higher risk of metastasis at the time of diagnosis and during follow-up.
Authors: María José Hernández-Corbacho; Russell W Jenkins; Christopher J Clarke; Yusuf A Hannun; Lina M Obeid; Ashley J Snider; Leah J Siskind Journal: PLoS One Date: 2011-06-08 Impact factor: 3.240
Authors: Simon Heumos; Sandra Dehn; Konstantin Bräutigam; Marius C Codrea; Christian M Schürch; Ulrich M Lauer; Sven Nahnsen; Michael Schindler Journal: Cancer Cell Int Date: 2022-10-11 Impact factor: 6.429